Skip to content

Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology

Longitudinal Prospective Study on Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Patients Using Caiman® Technology

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03219242
Acronym
CAIMAN
Enrollment
40
Registered
2017-07-17
Start date
2016-06-30
Completion date
2018-01-30
Last updated
2018-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Keywords

Advanced ovarian cancer

Brief summary

Longitudinal prospective study on primary debulking surgery including bowel resection in advanced stage ovarian cancer patients using Caiman® technology

Detailed description

Using CAIMAN® technology in primary surgery for advanced ovarian cancer including bowel resections. Analyze potential time-sparing and the incidence of post-surgical complications. Prospective, longitudinal, observational. 40 patients / year.

Interventions

DEVICECaiman® device

Using CAIMAN device in primary surgery for ovarian cancer. Analyze potential time-sparing and the incidence of post-surgical complications.

Sponsors

Catholic University of the Sacred Heart
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Age ≤ 75 years * Patients with advanced ovarian cancer (FIGO stage IIIC-IV). * Bowel resection * Class 0-2 according to the American Society of Anesthesiologists (i.e.: ASA score ≤ 2) * Written informed consent to the study

Exclusion criteria

* Pregnant or chronic infections * Previous pelvic radiotherapy

Design outcomes

Primary

MeasureTime frameDescription
time-sparing for bowel resectionup to 1 hourTime needed for bowel resection and radical omentecomy in avanced ovarian cancer
Post surgical complicationsUp to 6 monthsF-up in 1-3 and 6 months with questionnaire

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026